Biohit Oyj (BIOBV.HE)
EUR 2.72
(-1.2%)
EUR 2.72
(-1.2%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.68 Million EUR | 63.93% |
| 2022 | 1.34 Million EUR | 121.45% |
| 2021 | 692 Thousand EUR | 145.39% |
| 2020 | -1.25 Million EUR | -311.57% |
| 2019 | 778.99 Thousand EUR | 448.62% |
| 2018 | -188 Thousand EUR | -213.13% |
| 2017 | 7.41 Million EUR | 105.34% |
| 2016 | -2.91 Million EUR | 12.42% |
| 2015 | -2.58 Million EUR | 16.92% |
| 2014 | -4.05 Million EUR | 24.95% |
| 2013 | -5.65 Million EUR | -68.56% |
| 2012 | -3.25 Million EUR | -106.64% |
| 2011 | -1.34 Million EUR | 1625.59% |
| 2010 | 2.59 Million EUR | -13.38% |
| 2009 | 3.28 Million EUR | -7.81% |
| 2008 | 3.38 Million EUR | 201.78% |
| 2007 | 1.67 Million EUR | -24.37% |
| 2006 | 1.61 Million EUR | -12.07% |
| 2005 | 1.66 Million EUR | -7.85% |
| 2004 | 1.8 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 750 Thousand EUR | 0.0% |
| 2024 Q1 | 750 Thousand EUR | 140.0% |
| 2023 FY | - EUR | 63.93% |
| 2023 Q1 | 800 Thousand EUR | 715.38% |
| 2023 Q2 | 1.6 Million EUR | 100.0% |
| 2023 Q3 | 312.5 Thousand EUR | -80.47% |
| 2023 Q4 | 600 Thousand EUR | 92.0% |
| 2022 Q3 | -130 Thousand EUR | -108.13% |
| 2022 Q1 | 800 Thousand EUR | 14.29% |
| 2022 FY | - EUR | 121.45% |
| 2022 Q4 | -130 Thousand EUR | 0.0% |
| 2022 Q2 | 1.6 Million EUR | 100.0% |
| 2021 FY | - EUR | 145.39% |
| 2021 Q4 | 700 Thousand EUR | 225.58% |
| 2021 Q1 | -100 Thousand EUR | 48.72% |
| 2021 Q3 | 215 Thousand EUR | 171.67% |
| 2021 Q2 | -300 Thousand EUR | -200.0% |
| 2020 Q3 | -195 Thousand EUR | 80.5% |
| 2020 FY | - EUR | -311.57% |
| 2020 Q2 | -1 Million EUR | -100.0% |
| 2020 Q1 | -500 Thousand EUR | -600.0% |
| 2020 Q4 | -195 Thousand EUR | 0.0% |
| 2019 Q3 | -11.5 Thousand EUR | -102.88% |
| 2019 Q4 | 100 Thousand EUR | 969.57% |
| 2019 FY | - EUR | 448.62% |
| 2019 Q2 | 400 Thousand EUR | 100.0% |
| 2019 Q1 | 200 Thousand EUR | 827.27% |
| 2018 FY | - EUR | -213.13% |
| 2018 Q3 | -27.5 Thousand EUR | 45.0% |
| 2018 Q2 | -50 Thousand EUR | 0.0% |
| 2018 Q1 | -50 Thousand EUR | 98.74% |
| 2018 Q4 | -27.5 Thousand EUR | 0.0% |
| 2017 Q3 | -3.97 Million EUR | -205.95% |
| 2017 Q1 | 3.75 Million EUR | 605.39% |
| 2017 Q4 | -3.97 Million EUR | 0.0% |
| 2017 FY | - EUR | 105.34% |
| 2017 Q2 | 3.75 Million EUR | 0.0% |
| 2016 Q3 | -751.25 Thousand EUR | -12.09% |
| 2016 Q1 | -670.25 Thousand EUR | 55.32% |
| 2016 FY | - EUR | 12.42% |
| 2016 Q4 | -742 Thousand EUR | 1.23% |
| 2016 Q2 | -670.25 Thousand EUR | 0.0% |
| 2015 Q3 | -100 Thousand EUR | 75.0% |
| 2015 Q2 | -400 Thousand EUR | 55.56% |
| 2015 Q1 | -900 Thousand EUR | 25.56% |
| 2015 Q4 | -1.5 Million EUR | -1400.0% |
| 2015 FY | - EUR | 16.92% |
| 2014 Q1 | -1 Million EUR | 33.2% |
| 2014 FY | - EUR | 24.95% |
| 2014 Q4 | -1.2 Million EUR | -34.33% |
| 2014 Q3 | -900 Thousand EUR | 25.0% |
| 2014 Q2 | -1.2 Million EUR | -20.0% |
| 2013 Q3 | -900 Thousand EUR | 64.0% |
| 2013 Q4 | -1.49 Million EUR | -66.33% |
| 2013 Q1 | -1 Million EUR | -5.6% |
| 2013 Q2 | -2.5 Million EUR | -150.0% |
| 2013 FY | - EUR | -68.56% |
| 2012 FY | - EUR | -106.64% |
| 2012 Q3 | -600 Thousand EUR | 50.0% |
| 2012 Q2 | -1.2 Million EUR | -100.0% |
| 2012 Q4 | -947 Thousand EUR | -57.83% |
| 2012 Q1 | -600 Thousand EUR | -101.3% |
| 2011 Q4 | 46.32 Million EUR | 4111.27% |
| 2011 Q1 | 900 Thousand EUR | 66.36% |
| 2011 Q2 | 600 Thousand EUR | -33.33% |
| 2011 Q3 | 1.1 Million EUR | 83.33% |
| 2011 FY | - EUR | 1625.59% |
| 2010 Q2 | 900 Thousand EUR | 28.57% |
| 2010 Q3 | 700 Thousand EUR | -22.22% |
| 2010 Q1 | 700 Thousand EUR | -45.31% |
| 2010 Q4 | 541 Thousand EUR | -22.71% |
| 2010 FY | - EUR | -13.38% |
| 2009 Q1 | 500 Thousand EUR | 0.0% |
| 2009 FY | - EUR | -7.81% |
| 2009 Q4 | 1.28 Million EUR | 113.33% |
| 2009 Q3 | 600 Thousand EUR | -14.29% |
| 2009 Q2 | 700 Thousand EUR | 40.0% |
| 2008 FY | - EUR | 201.78% |
| 2007 FY | - EUR | -24.37% |
| 2006 FY | - EUR | -12.07% |
| 2005 FY | - EUR | -7.85% |
| 2004 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Herantis Pharma Oyj | 831.43 Thousand EUR | -223.416% |
| Nanoform Finland Oyj | -17.65 Million EUR | 115.233% |